Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.37 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457557 | 1.00 | NOS1 (0.40) | NOS1PTGS1SLC7A11NOS3NOS2 | |
| Ammonia Solution, Strong SCHEMBL7568632 | 0.98 | NOS1 (0.39) | NOS1PTGS1SLC7A11NOS3NOS2 | |
| Nitric Acid SCHEMBL27650216 | 0.96 | NOS1 (0.38) | NOS1PTGS1SLC7A11NOS3NOS2 | |
| SCHEMBL456815 | 0.79 | NOS1 (0.45) | NOS1NOS3NOS2GRIA1GRIA2 | |
| Nitric Acid SCHEMBL457952 | 0.76 | NOS1 (0.42) | NOS1NOS3NOS2GRIA1GRIA2 | |
| Nitric Acid SCHEMBL457953 | 0.76 | NOS1 (0.42) | NOS1NOS3NOS2GRIA1GRIA2 | |
| SCHEMBL13397063 | 0.76 | CA12 (0.41) | NOS1NOS3NOS2SLC1A5 | |
| SCHEMBL13396930 | 0.76 | CA12 (0.38) | NOS1NOS3NOS2SLC1A5 | |
| SCHEMBL5154144 | 0.76 | SLC1A1 (0.42) | NOS1NOS3NOS2GRIA1GRIA2 | |
| SCHEMBL13397064 | 0.75 | NOS1 (0.37) | NOS1PTGS1NOS3NOS2SLC1A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504956-A1 | MODIFIED SOPHOROLIPID FOR IMPROVED BIOAVAILABILITY OF AMINO ACIDS AND METHOD OF USE | Locus Solutions IPCO, LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196890-A1 | MODIFIED SOPHOROLIPID FOR IMPROVED BIOAVAILABILITY OF AMINO ACIDS AND METHOD OF USE | LOCUS SOLUTIONS IPCO, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-2614050-B1 | 1,5-DIARYL-2-ALKYLPYRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | Rottapharm Biotech Srl (IT) | 2016-01-20 | — | — | EP | disclosed |
| US-9162979-B2 | 1,5-Diary1-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitric oxide donors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-10-20 | — | — | US | disclosed |
| EP-2614050-A1 | 1,5-DIARYL-2-ALKYLPYRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | Rottapharm S.p.A. (IT) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | ROTTAPHARM S.P.A. (IT) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032479-A1 | L,5-DIARYL-2-ALKVLPVRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | ROTTAPHARM S.P.A. (IT) | 2012-03-15 | — | — | WO | disclosed |
| CN-100513415-C | Bile acid derivative and pharmaceutical use thereof | INST PHARM & TOXICOLOGY AMMS (CN) | 2009-07-15 | — | — | CN | disclosed |
| CN-1908001-A | Bile acid derivative and pharmaceutical use thereof | POISON MED INST PLA MED ACAD (CN) | 2007-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | NOS3, PTGER3, PTGES3 | NOS1 14/4885PTGS1 12/4885SLC7A11 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.